The company · the work · the direction
The pharmaceutical company being built around what medicine needs next
You should not have to choose between better medicines intelligence and the capability to act on it. NEUVIOR is building from PHARMORIS towards a connected pharmaceutical company spanning governed technology, development and future delivery.
Why NEUVIOR exists
You can have the evidence and still fail to move the medicine.
Medicines decisions rarely fail because nobody produced a spreadsheet, policy or clinical paper. They fail when the basis of the decision, accountable owner, implementation work and later review become separated across teams and systems.
NEUVIOR was created to close that distance. The company starts with medicines intelligence and governed execution, then builds towards the development and delivery capabilities needed to carry a pharmaceutical opportunity further.
See what matters
Bring source linked evidence, assumptions and uncertainty into one understandable decision context.
Medicines intelligenceMake the decision ownable
Keep human authority, the accountable owner and the reason for progression or refusal visible.
Governed technologyCarry it into delivery
Connect tasks, blockers, dependencies and review so the insight does not die after the meeting.
Operating infrastructureWhat NEUVIOR does today
Start with one consequential workflow. Build the institution around it.
PHARMORIS is the company’s immediate product priority: a configurable, human governed medicines operations system under controlled development. It is designed for the work after a signal is identified: triage, evidence, ownership, decision, coordination and value review.
Varun is developing VARUNÉ Labs as a predevelopment programme operated by NEUVIOR PHARMACEUTICALS LTD (SC857853). Its interests span medicines, novel formulations, generics, skincare and personal care, fragrance research and future manufacturing planning. Facilities and manufacturing remain future ambitions.
PHARMORIS
Help an authorised team move from medicines evidence to a governed ActionCase and reviewable result.
Current product priorityVARUNÉ medicines and formulation
A NEUVIOR operated predevelopment programme exploring scientific and partner routes for medicines, novel formulations, generics and personal care.
Predevelopment programmeVARUNÉ future manufacturing
Longer range planning for pharmaceutical facilities and manufacturing, subject to capability, approvals, quality systems and economics.
Predevelopment programmeThe opening year
Momentum should buy better execution, not louder claims.
NEUVIOR has been selected for non-dilutive support for defined project work. Published award records are source linked. Award ceilings, eligible project costs, company contributions and cash received are different figures; none is customer revenue, equity raised, adoption or an outcome.
The company has also built a growing public record across pharmaceutical trade, technology and business media, while developing a connected working presence through Glasgow, London and Mumbai.
Source linked project support
Published project records retain their own value, status, provider and evidence boundary rather than being collapsed into one aggregate claim.
Non dilutive supportSource linked media record
Reporting, founder commentary, partner announcements, editorial roundups and labelled syndication in the current newsroom ledger.
Classified public recordThree connected cities
Scottish origin, founder led UK commercial work and India facing pharmaceutical engagement.
Glasgow · London · MumbaiWhat NEUVIOR stands for
Move with ambition. Keep the decision defensible.
NEUVIOR is designed for high consequence work. Speed matters, but only when the source, authority and next action remain clear. Commercial scale matters because it can compound useful pharmaceutical capability over time.
Make evidence useful
A source creates value when the people responsible can understand it, decide and act.
Keep authority human
Technology should make responsibility visible, not inherit clinical or institutional authority.
Build for compounding value
Products, scientific capability, relationships and operating knowledge should strengthen the next move.
Think internationally
Connect British pharmaceutical innovation with the markets, talent and capability needed for global relevance.
- Podcast appearance. AI Ethics Now / University of Warwick IATL. AI and Accountability: When Does a Suggestion Become a Decision?. 23 August 2026.
- Contributed analysis. Pharmaphorum. Approval is not access: Pilots' real test is implementation. 18 August 2026.
- Contributed opinion. TechRadar Pro. Five questions to test whether an AI stack is truly under your control. 11 August 2026.
- Founder commentary. ET Pharma. India’s pharma quality reset will be won after the inspector leaves. 4 August 2026.
- NEUVIOR analysis. NEUVIOR Founder Reflections. From invention to adoption: the work between. 3 August 2026.
- NEUVIOR analysis. NEUVIOR Founder Reflections. A trade deal is not a patient pathway. 3 August 2026.
- NEUVIOR analysis. NEUVIOR Insights. NHS digital programmes do not fail on dashboards. They fail on deployment. 20 March 2026.
- Founder viewpoint. Pharmaceutical Technology. Why the India UK trade deal now needs a five gate implementation ledger. 28 July 2026.
- Release derived reporting. TheBusinessDesk.com. NEUVIOR company support coverage. 19 May 2026.
- Founder commentary. Startups Magazine. What my dad's corner shop taught me. 6 May 2026.
- Expert commentary. Manufacturing Chemist. NICE approval is not enough: why the UK's next medicines challenge is operational delivery. 4 June 2026.
- Founder commentary. PharmaTimes. How we roll. 10 June 2026.
- Founder commentary. BusinessCloud. Why neurodivergent founders can excel at building complex systems. 18 March 2026.
- Partner announcement. Biorenewables Development Centre. NEUVIOR research record. 20 April 2026.
Classified public record
IDEAS + PUBLIC RECORD
See how the company thesis becomes an operating sequence.
Start with the medicines problem, follow the founder’s case for connected intelligence and development, then inspect the public record behind the company.
AI and Accountability: When Does a Suggestion Become a Decision?
Varun Sharma joins AI Ethics Now to examine false confidence, human responsibility and the point where AI assisted suggestions become accountable decisions.
Listen to the AI Ethics Now conversationApproval is not access: Pilots' real test is implementation
In pharmaphorum, Varun Sharma argues that medicines access pilots should measure the full chain from recommendation to funded delivery and outcomes.
Read why approval is not accessFive questions to test whether an AI stack is truly under your control
In TechRadar Pro, Varun Sharma sets out five tests for enterprise AI control across provenance, infrastructure, legal authority and safe exit.
Test whether an AI stack is truly controlled
NEUVIOR Insights and After Publication reflections are company or founder analysis. Publisher records evidence publication, not endorsement, adoption, product readiness, savings or clinical outcomes.
Make the next step useful
Bring the problem that needs a clearer decision.
Tell us what is stuck, what decision you need to make and what a better outcome would change. We will connect you to the most relevant NEUVIOR, PHARMORIS, media or investor route.